- BySeeking Alpha-
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated...
Werewolf Therapeutics (HOWL): Q1 GAAP EPS of -$83.36.As of March31, 2021, cash and cash equivalents decreased to $84.6M, compared to $92.6M as of December31, 2020
Werewolf Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing a pipeline of cancer treatments. It is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is design to conditionally activate molecules that stimulate both adaptive and innate immunity with addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, is intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which is used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The Company using PREDATOR platform, have developed three initial product candidates: WTX-124, WTX-330 and WTX-613.